We propose to develop within the Division of Oncology at the Fred Hutchinson Cancer Research Center a program devoted to the study and treatment of aplastic anemia. In vitro laboratory studies involving culture of hemopoietic cells will focus on the etiology of the disease; in vitro results will be correlated with clinical response to therapy. Monoclonal antibodies to T cell subsets will be used to dissect the role of lymphocytes in in vitro hemopoiesis. Results might help us in choosing the most suitable antibody for in vivo treatment of patients. Several treatment modalities will be evaluated in the setting of optimal supportive care which includes platelet transfusions, laminar air flow isolation, gut sterilization, bacteria-poor diet and, if necessary, granulocyte transfusions. Treatment with intensive supportive care alone will be compared to immunosuppressive therapy using either horse antihuman thymocyte globulin or monoclonal antibolies to T lymphocyte from HLA identical family members using a new conditioning regimen and a pos-grafting immunosuppresive therapy regimen involving cyclosporin A to reduce the rates of marrow graft rejection and graft-versus-host disease. A marrow transplant regimen for less well matched donors is proposed to obtain information on the importance of histcompatibility. Research on long term platelet support and management of infectious complications in this group of patients is proposed. Studies on immunologic reconstitution and long-term follow-up will be carried out. Data processing and biostatistic analyses will provide maximun utilization of information generated. Some of the principles derived from these studies will be applicable to the treatment of other diseases, e.g. thalassemia major, sickle cell disease and hematologic malignancy.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL036444-07
Application #
3098458
Study Section
Heart, Lung, and Blood Research Review Committee B (HLBB)
Project Start
1986-07-01
Project End
1991-06-30
Budget Start
1987-07-01
Budget End
1988-06-30
Support Year
7
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Thakar, M S; Bonfim, C; Walters, M C et al. (2017) Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia. Bone Marrow Transplant 52:570-573
Burroughs, Lauri M; Shimamura, Akiko; Talano, Julie-An et al. (2017) Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders. Biol Blood Marrow Transplant 23:1669-1677
Vaughn, J E; Anwer, F; Deeg, H J (2016) Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom? Vox Sang 110:5-11
Aki, S Z; Inamoto, Y; Carpenter, P A et al. (2016) Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity. Bone Marrow Transplant 51:1350-1353
Khera, Nandita; Gooley, Ted; Flowers, Mary E D et al. (2016) Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 22:1319-1323
Karoopongse, Ekapun; Marcondes, A Mario; Yeung, Cecilia et al. (2016) Disruption of Iron Regulation after Radiation and Donor Cell Infusion. Biol Blood Marrow Transplant 22:1173-1181
Hoffmeister, P A; Storer, B E; Syrjala, K L et al. (2016) Physician-diagnosed depression and suicides in pediatric hematopoietic cell transplant survivors with up to 40 years of follow-up. Bone Marrow Transplant 51:153-6
Gallo, S; Woolfrey, A E; Burroughs, L M et al. (2016) Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD? Bone Marrow Transplant 51:1573-1578
Festuccia, Moreno; Deeg, H Joachim; Gooley, Theodore A et al. (2016) Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. Biol Blood Marrow Transplant 22:1227-1233

Showing the most recent 10 out of 788 publications